demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
infections other than COVID-19
potential COVID-19 treatments
adjuvant therapies
face mask MacIntyre ... MacIntyre ...
anti-inflammatoty and immuno-therapy
Immunostimulants drugs
convalescent plasma treatment Hung IRC002 Study Team IRC005 Study Team INSIGHT FLU-IVIG ...
antiviral and associated therapy
chloroquine and derivatives CuraChik ... Peymani Borges Paton Tricou
vaccines
ebola vaccine Ishola ... EBOVAC2
Non replicating viral vector
Ad26.RSV.preF (respiratory syncytial virus) Sadoff
Ad26.ZEBOV () Afolabi
Ad26.ZIKV.001 (Ad26-Vectored Anti-Zika Virus Vaccine) Salisch

12 studies excluded by filtering options 2

5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble